Liss Howard
Rokach Center for the Prevention of Lung Diseases, Clalit Health Services, and Tuberculosis Treatment and Prevention Unit, Jerusalem, Israel.
Isr Med Assoc J. 2006 Jul;8(7):451-4.
A publication bias exists towards positive results in studies funded by pharmaceutical companies.
To determine whether drug studies in the pulmonary/allergy literature also demonstrate a publication bias towards more favorable results when a pharmaceutical company funds the study.
We reviewed all original articles published in seven pulmonary and allergy journals between October 2002 and September 2003. Included in the review were studies of inhaled corticosteroids (oral or nasal), long- or short-acting bronchodilators, or leukotriene receptor antagonists. Articles with funding from a pharmaceutical company and/or one or more authors employed by a pharmaceutical company were considered pharmaceutical company-sponsored studies. The remaining studies were considered not sponsored by a pharmaceutical company. Results were compared to ascertain whether positive results were obtained more frequently in the company-sponsored studies.
Of the 100 articles included in this review 63 were considered pharmaceutical company-sponsored research. Results favorable for the drugs studies were significantly more common in those funded by a pharmaceutical company (98% vs. 32%).
In the pulmonary and allergy literature, as in other fields, there is a publication bias towards positive results in pharmaceutical company-sponsored research.
由制药公司资助的研究中存在对阳性结果的发表偏倚。
确定在肺部/过敏文献中的药物研究，当由制药公司资助时，是否也表现出对更有利结果的发表偏倚。
我们回顾了2002年10月至2003年9月期间在7种肺部和过敏期刊上发表的所有原创文章。纳入回顾的有吸入性皮质类固醇（口服或鼻用）、长效或短效支气管扩张剂或白三烯受体拮抗剂的研究。来自制药公司资助和/或由制药公司雇佣的一名或多名作者撰写的文章被视为制药公司赞助的研究。其余研究被视为非制药公司赞助。比较结果以确定在公司赞助的研究中是否更频繁地获得阳性结果。
在本回顾纳入的100篇文章中，63篇被视为制药公司赞助的研究。在制药公司资助的研究中，对药物研究有利的结果明显更常见（98%对32%）。
与其他领域一样，在肺部和过敏文献中，制药公司赞助的研究存在对阳性结果的发表偏倚。
